Refining the definition of clinically important mineral and bone disorder in hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 30, Issue 8, 2015, Pages 1336-1344

  Danese, Mark D ^a   Halperin, Marc ^a   Lowe, Kimberly A ^b   Bradbury, Brian D ^b   Do, Thy P ^b   Block, Geoffrey A ^c  

^a Outcomes Insights Inc ^*  (United States)

^b AMGEN INC   (United States)

^c Denver Nephrologists PC   (United States)

Author keywords

cardiovascular disease; CKD MBD; death; hemodialysis; risk prediction

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D; BIOLOGICAL MARKER; MINERAL;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; COHORT ANALYSIS; DEATH; FEMALE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; MINERAL AND BONE DISORDER; NEWBORN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION SIZE; PRIORITY JOURNAL; VERY ELDERLY; BLOOD; HEMODIALYSIS; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BONE DISEASES, METABOLIC; CALCIUM; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MINERALS; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; YOUNG ADULT;

EID: 84939621478     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv034     Document Type: Article

References (24)

1. Martin KJ, Gonzalez EA. Metabolic bone disease in chronic kidney disease. J Am Soc Nephrol 2007; 18: 875-885
2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
3. Moe SM, Drueke T, Lameire N et al. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12
4. NKF. KDOQI Guidelines for CKD Care. Available from URL: http://www. kidney.org/professionals/kdoqi/guidelines-commentaries.cfm 2013
5. NKF. KDIGO: Kidney Disease-ImprovingGlobalOutcomesClinical Practice Guidelines. Available from URL: http://kdigo.org/home/guidelines/2013
6. Martin KJ, Gonzalez EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat? Clin J Am Soc Nephrol 2011; 6: 440-446
7. Bover J, Farre N, Andres E et al. Update on the treatment of chronic kidney disease-mineral and bone disorder. J Ren Care 2009; 35(Suppl 1): 19-27
8. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
9. Danese MD, Belozeroff V, Smirnakis K et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429
10. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357
11. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). AmJ Kidney Dis 2008; 52: 519-530
12. Block GA. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality. Curr Opin Nephrol Hypertens 2011; 20: 376-381
13. Block GA, Kilpatrick RD, Lowe KA et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 2013; 8: 2132-2140
14. Cozzolino M, Urena-Torres P, VervloetMG, et al. Is chronic kidney diseasemineral bone disorder (CKD-MBD) really a syndrome? Nephrol Dial Transplant 2014; 68: 429-436
15. USRDS. Annual Data Report 2012
16. Liu J, Huang Z, Gilbertson DT et al. An improved comorbidity index for outcome analyses among dialysis patients. Kidney Int 2010; 77: 141-151
17. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf 2012; 21(S2): 138-147
18. Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation and Updating. New York, NY: Springer, 2010
19. Medicare Program: End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies: Department of Health and Human Services; Centers for Medicare & Medicaid Services 2013
20. CMS. ESRD QIP Payment Year 2015 Program Details. Available from URL: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/ESRDQIP/Downloads/QIP-Details-PY15.pdf
21. CMS. ESRD QIP Payment Year 2016 Program Details. Available from URL: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment- Instruments/ESRDQIP/Downloads/QIP-Details-PY16.pdf
22. Brunelli SM, Monda KL, Burkart JM et al. Early trends from the Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations (STEPPS). Am J Kidney Dis 2013; 61: 947-956
23. Powe NR, Griffiths RI, Anderson GF et al. Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. Am J Kidney Dis 1993; 22: 557-567
24. Steyerberg EW, Eijkemans MJ, Boersma E et al. Applicability of clinical prediction models in acute myocardial infarction: a comparison of traditional and empirical Bayes adjustment methods. Am Heart J 2005; 150: 920